57 F.4th 17
1st Cir.2023Background
- Gregory (Father Emmanuel) Lemelson managed the Amvona Fund and published investment reports (including on Seeking Alpha) while holding a significant short position in Ligand Pharmaceuticals stock.
- In June–August 2014 Lemelson made three contested statements: (1) that Ligand’s investor-relations rep (Voss) said Ligand understood its key drug Promacta was "going away" (Promacta Statement); (2) that Viking Therapeutics "does not intend to conduct any preclinical studies or trials" (Preclinical Studies Statement); and (3) that Viking’s S-1 financials were unaudited (Audit Statement) (the last two, the Viking Statements).
- Viking’s S-1, publicly filed, stated Viking intended to rely on third parties for trials and included audited financial data; Lemelson acknowledged reading the S-1.
- The SEC sued Lemelson under Section 10(b) and Rule 10b-5 for making untrue statements of material fact; after trial a jury found him liable on the three statements.
- The district court imposed a $160,000 civil penalty and a five-year injunction against future Rule 10b-5/Section 10(b) violations; Lemelson appealed.
Issues
| Issue | Plaintiff's Argument (SEC) | Defendant's Argument (Lemelson) | Held |
|---|---|---|---|
| Whether the Viking Statements are nonactionable opinion protected by the First Amendment | Statements asserted objective facts (unaudited; no intent to conduct studies); contradicted S-1; therefore factual and actionable | They were interpretive opinions based on S-1 data and thus protected expression | Court: Viking Statements were provable, factual (or misleading half-truths), not protected opinion; jury could find them factual |
| Materiality of the Promacta and Viking Statements | Each statement concerned matters a reasonable investor would view as significantly altering the total mix (Promacta key revenue; Viking central to Ligand’s prospects) | Public S-1 already disclosed Viking’s audited data and trial plans; Promacta context was publicly known; statements therefore immaterial | Court: Sufficient evidence for a rational jury to find materiality for all three statements |
| Scienter (intent or severe recklessness) | Lemelson was a sophisticated, active hedge-fund manager who read the S-1 and benefited from short positions; failing to correct contrary facts supports intent/recklessness | No proof he knowingly or recklessly misled; at most mistake or interpretation | Court: Evidence supports scienter—jury reasonably could infer intentional misstatement or high degree of recklessness |
| Whether five-year injunction was an abuse of discretion | Injunction appropriate given egregious misstatement, personal profit, ability to reoffend, and lack of remorse | Injunction improper or excessive; district court misstated standard (possibility vs likelihood) | Court: No abuse; district court applied "reasonable likelihood of recidivism" factors and reasonably limited injunction to five years |
Key Cases Cited
- Omnicare, Inc. v. Laborers Dist. Council Constr. Indus. Pension Fund, 575 U.S. 175 (2015) (distinguishes statements of fact from opinion; certainty test)
- Basic Inc. v. Levinson, 485 U.S. 224 (1988) (materiality: information that would significantly alter total mix)
- TSC Indus., Inc. v. Northway, Inc., 426 U.S. 438 (1976) (formulation of materiality standard)
- Constr. Indus. & Laborers Joint Pension Tr. v. Carbonite, Inc., 22 F.4th 1 (1st Cir. 2021) (fact/opinion analysis; product importance in materiality)
- SEC v. Johnston, 986 F.3d 63 (1st Cir. 2021) (half-truths can be misleading; scienter in misstatements)
- McKee v. Cosby, 874 F.3d 54 (1st Cir. 2017) (First Amendment/defamation framework for opinion vs provable fact)
- SEC v. Sargent, 329 F.3d 34 (1st Cir. 2003) (standard for SEC injunctions: reasonable likelihood of recidivism; multi-factor review)
- SEC v. Ficken, 546 F.3d 45 (1st Cir. 2008) (scienter defined as intent to defraud or a high degree of recklessness)